3D Liver-Mimetic Device Using DOPsL for Hepatic Function Simulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current liver models for drug screening and transplantation are limited by suboptimal cell sourcing, inability to fully replicate native liver tissue architecture, and inefficiencies in detoxification of pore-forming toxins, leading to unreliable drug testing and high drug failure rates.
Innovation Solution
A 3D liver-mimetic device is fabricated using dynamic optical projection stereolithography (DOPsL) to create a biomimetic structure with hepatic progenitor cells or polydiacetylene nanoparticles, closely mimicking liver microarchitecture and function, enabling effective drug metabolism studies and toxin neutralization.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional liver models (liver slices, cell lines, primary hepatocytes) are used for drug screening, then drug metabolism studies can be conducted, but the models fail to fully replicate native liver tissue architecture and cellular responses, leading to unreliable results
Solution Approach 1:
The patent employs a 3D porous scaffold that replicates the native liver tissue architecture, allowing cells to be embedded within a structure that mimics the natural extracellular matrix. This porous structure enables proper cell-cell and cell-matrix interactions, thereby improving both the architectural fidelity and the reliability of drug metabolism studies.
Solution Approach 2:
The invention combines multiple materials including biocompatible polymers, growth factors, and cellular components to create a composite liver tissue model. This composite approach allows simultaneous replication of structural architecture, biochemical environment, and cellular function, resolving the contradiction between manufacturing precision and reliability.
2Productivity
If iPSC technology is used to source hepatic progenitor cells, then a limitless supply of hepatocytes with robust proliferative capacity can be obtained, but the safety of iPSCs for clinical applications remains limited
Solution Approach 1:
The patent uses hepatic progenitor cells as an intermediary stage between iPSCs and mature hepatocytes. The progenitor cells serve as a transition state that can be expanded and differentiated in a controlled manner, providing a safer intermediate step that maintains proliferative capacity while reducing the direct clinical safety concerns associated with undifferentiated iPSCs.
Solution Approach 2:
The invention performs preliminary differentiation of iPSCs into hepatic progenitor cells before final hepatocyte generation. This preliminary action allows for quality control, characterization, and selection of safe, functional progenitor populations before committing to full differentiation, thereby addressing safety concerns while preserving productivity.
3Reliability
If primary hepatocytes are cultured in conventional 2D systems, then they serve as the gold standard for in vitro applications, but they lack robust proliferative capacity and de-differentiate quickly, maintaining functional activity for only 24-72 hours
Solution Approach 1:
The patent transitions from conventional 2D culture to a 3D tissue model, embedding hepatocytes within a three-dimensional scaffold. This dimensional change provides mechanical support, improves nutrient and oxygen diffusion, and maintains cell polarity and architecture, thereby extending the duration of functional activity while preserving reliability.
Solution Approach 2:
The invention changes multiple parameters including oxygen tension, nutrient composition, growth factor concentrations, and mechanical stiffness of the scaffold to create an optimized microenvironment. These parameter changes collectively extend the functional lifespan of hepatocytes from 24-72 hours to prolonged periods while maintaining their functional activity.
4Reliability
If polydiacetylene nanoparticles are used for toxin capture, then effective neutralization of pore-forming toxins can be achieved, but the complexity of the detoxification system increases
Solution Approach 1:
The patent employs polydiacetylene nanoparticles that autonomously capture and neutralize pore-forming toxins through their inherent molecular structure. The nanoparticles self-assemble and self-react with toxins without requiring external activation or complex control systems, thereby achieving high neutralization efficiency while minimizing system complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The device provides a reliable, cost-efficient platform for preclinical drug screening and hepatology research, reducing drug development costs and improving toxin neutralization efficiency, while allowing for patient-specific models and personalized disease simulations.
Implementation Method 1
a 3D liver-mimetic structure can be fabricated using DOPsL to closely mimic hepatic micro-architecture and function
Implementation Method 2
The step of photopolymerizing comprises using dynamic optical projection stereolithography
Data Source
AI summary
A liver-mimetic device and method include a 3D polymer scaffold having a matrix of liver-like lobules with hepatic-functioning particles encapsulated within the lobules. In some embodiments, each liver-like lobule is hexagonal in structure and the matrix is in a honeycomb arrangement. In some embodiments, the hepatic-functioning particles are hepatic progenitor cells. In other embodiments, the hepatic-functioning particles are polymer nanoparticles adapted to capture pore-forming toxins.